Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The HERMES Study

NCT00297115 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00297115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00297115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The HERMES Study
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2006
Completion date
August 31, 2008
Enrollment
1,568 (actual)
Sites
287

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)